Table 2. Details of treatment for advanced disease.

Characteristic	All patients [N=382]	Long-term responders [N=123]	Controls [N=259]	P value
First-line chemotherapy cycles				<0.001
Median [range]	6 [2-47]	12 [9-47]	4 [2-8]
First-line chemotherapy regimen N, [%]				0.007
Fluoropyrimidine	11 [3]	9 [3]	2 [2]
Gemcitabine- Fluoropyrimidine	156 [41]	93 [36]	63 [51]
Gemcitabine-Platinum	155 [41]	109 [42]	46 [37]
Gemcitabine-Platinum + Selumetinib	10 [3]	5 [2]	5 [4]
Gemcitabine	43 [11]	37 [14]	6 [5]
Other	7 [2]	6 [2]	1 [1]
Radiographic response N, [%]				<0.001
Complete regression	3 [1]	3 [2]	0
Partial regression	116 [32]	71 [59]	46 [19]
Stable imaging	142 [40]	47 [39]	95 [40]
Disease progression	97 [27]	0	96 [41]
Missing	24	2	22
Chemotherapy toxicity N, [%]†
Neutropenia	74 [19]	37 [30]	37 [14]	<0.001
Thrombocytopenia	77 [20]	32 [26]	45 [17]	0.056
Neuropathy	11 [3]	6 [5]	6 [2]	0.21
Nephropathy	11 [3]	6 [5]	5 [2]	0.19
Nausea/vomiting	105 [27]	45 [37]	60 [23]	0.007
Sepsis/infection	73 [19]	24 [20]	49 [19]	0.89
Skin toxicity	69 [18]	39 [32]	30 [12]	<0.001
Reason for stopping N, [%]				0.96
Disease progression	219 [57]	69 [56]	150 [58]
Toxicity	48 [13]	17 [14]	31 [12]
Planned/patient request	76 [20]	24 [19]	52 [20]
Other	39 [10]	13 [11]	26 [10]
Chemotherapy break >3 months N, [%]	20 [5]	19 [15]	1 [1]	<0.001
Second-line chemotherapy N, [%]	142 [37]	58 [47]	84 [33]	0.007
Median cycles [range]		3 [1-21]	3 [1-18]
Third-line chemotherapy [N, %]	48 [13]	22 [18]	26 [10]	0.046
Radiotherapy details‡				0.09
Stereotactic/fractionated RT to primary tumor	33 [9]	15 [12]	18 [7]
Palliative RT	40 [10]	11 [9]	29 [11]

^†, Any cycle; ^‡, for advanced disease, either before or after first-line palliative chemotherapy. RT, radiotherapy.